Slocum, Gordon & Co’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$237K Hold
562
– – 0.17% 61
2026
Q2
$204K Buy
+562
New +$192K 0.14% 68
2025
Q3
– Sell
-562
Closed -$157K – 58
2025
Q2
$157K Hold
562
– – 0.13% 63
2025
Q1
$175K Sell
562
-563
-50% -$166K 0.13% 57
2024
Q4
$293K Hold
1,125
– – 0.24% 45
2024
Q3
$362K Hold
1,125
– – 0.15% 46
2024
Q2
$352K Hold
1,125
– – 0.26% 41
2024
Q1
$320K Hold
1,125
– – 0.24% 43
2023
Q4
$324K Hold
1,125
– – 0.28% 40
2023
Q3
$302K Hold
1,125
– – 0.26% 43
2023
Q2
$250K Buy
1,125
+63
+6% +$14.6K 0.18% 44
2023
Q1
$257K Hold
1,062
– – 0.21% 43
2022
Q4
$279K Buy
+1,062
New +$285K 0.18% 44

Other funds holding AMGN

Slocum, Gordon & Co's AMGN Position: Q3 2026 in Review

Slocum, Gordon & Co held its Amgen (AMGN) position steady in Q3 2026 at 562 shares worth $237K. The position accounts for 0.17% of the portfolio, ranked #61.

Slocum, Gordon & Co first reported a position in AMGN in Q4 2022 and has held it in 13 quarters since. The position peaked at $362K in Q3 2024. 3,271 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • Slocum, Gordon & Co held 562 shares of Amgen worth $237K as of Q3 2026.
  • Slocum, Gordon & Co left its Amgen share count unchanged in Q3 2026.
  • Amgen made up 0.17% of Slocum, Gordon & Co's portfolio in Q3 2026, its #61 holding.
  • Slocum, Gordon & Co first reported a position in Amgen in Q4 2022 and has held it in 13 quarters since.
  • Slocum, Gordon & Co's Amgen position peaked at $362K in Q3 2024.
  • 3,271 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on Slocum, Gordon & Co's 13F filing for Q3 2026, filed 19 Oct 2026.